MedPath

Tagged News

MEDiC Life Sciences Acquires Clinical-Stage Oncology Program Using SLS Biomarker Platform for Precision Medicine

Precision MedicineOncology
  • MEDiC Life Sciences announced its first acquisition of a clinical-stage therapeutic program that completed Phase 1 dose escalation studies, marking the company's strategic pivot toward building a therapeutic pipeline.
  • The acquisition was validated through MEDiC's proprietary SLS (Synthetic-Lethal-Gene Signature) biomarker platform, which generates millions of biomarker combinations in 3D cancer models to optimize patient selection criteria.
  • The program targets a key oncogenic driver where the field has struggled to identify the correct patient cohort, with MEDiC planning to initiate biomarker-driven clinical development next year.
  • This acquisition serves as proof of concept for MEDiC's platform to identify undervalued therapeutic assets and advance precision medicines faster and at lower cost for cancer patients.

Myriad Genetics and SOPHiA GENETICS Partner to Develop Global Liquid Biopsy Companion Diagnostic Platform

Precision MedicineOncology
  • Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration to develop an innovative global liquid biopsy companion diagnostic test for pharmaceutical companies.
  • The partnership will leverage Myriad's advanced U.S. laboratory capabilities and SOPHiA GENETICS' decentralized network of over 800 connected institutions across 70+ countries.
  • The collaboration initially focuses on MSK-ACCESS® powered with SOPHiA DDM™, a liquid biopsy test that detects actionable genomic alterations from circulating tumor DNA.
  • This hybrid regulatory approach aims to provide pharmaceutical partners with access to key regulated markets globally while expanding patient access to personalized cancer care.

N4 Pharma's Nuvec Delivery System Achieves Targeted RNA Delivery to Lung Cancer Cells

Precision Medicine
  • N4 Pharma's Nuvec gene delivery system successfully demonstrated targeted delivery of RNA to non-small cell lung cancer cells in collaboration with SRI International.
  • The precision targeting was achieved by functionalising Nuvec with molecules that bind to αvβ6 protein, which is highly expressed in epithelial cancers including lung, breast, prostate and pancreatic cancers.
  • Targeted Nuvec particles showed selective uptake with RNA payloads delivered only by functionalised particles, validating the system as a differentiated delivery platform for RNA therapies.
  • The breakthrough addresses a major challenge in oncology by potentially enabling more effective treatments with fewer toxic side effects through precise cancer cell targeting.

MMRF Presents Breakthrough Multiple Myeloma Research at International Conference, Revealing Immune System Changes During Treatment

Precision Medicine
  • The Multiple Myeloma Research Foundation presented 23 research abstracts at the 22nd International Myeloma Society Annual Meeting, including five direct presentations and 18 studies based on their flagship programs.
  • Key findings from the MyDRUG precision medicine trial demonstrated how daratumumab-based quadruplet therapy reshapes T cell populations in bone marrow, highlighting immune function's critical role in current therapies.
  • The Immune Atlas program revealed how the immune system changes during multiple myeloma treatment through longitudinal multi-omic profiling that uncovers immune escape mechanisms and response predictors.
  • MMRF's research initiatives have contributed to tripling life expectancy for multiple myeloma patients, with the foundation having raised over $600 million for research and helped bring 15+ FDA-approved therapies to market.

GeneDx Strengthens Leadership Team with Key Appointments to Advance AI-Powered Precision Medicine

AIPrecision MedicineRare DiseaseDrug Discovery
  • GeneDx appointed Lisa Gurry as Chief Business Officer to lead strategic partnerships and unlock the potential of GeneDx Infinity, the world's largest rare disease dataset with nearly one million exomes and genomes.
  • The company also named Dr. Thomas Fuchs, Chief AI Officer at Eli Lilly, to its board of directors to advance AI applications in genomic medicine and drug discovery.
  • These appointments position GeneDx to accelerate precision medicine initiatives, leveraging AI tools like Multiscore and recent acquisitions such as Fabric Genomics to improve diagnostic efficiency.
  • The strategic moves aim to enhance partnerships with biopharma companies and health systems while delivering faster, more accurate rare disease diagnoses for patients and families.

Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery to Accelerate RNAi Drug Development

Precision MedicineDrug Discovery
  • Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.
  • The partnership will enable Alnylam to leverage AI-powered genomic data to identify new therapeutic targets for gene silencing medicines, with the alliance expanding to include an additional 31,250 whole-genomes.
  • The AGD dataset has already demonstrated value by identifying novel therapeutic targets in autoimmune and neurodegenerative diseases, with plans to add multiomic layers including proteomics to enhance drug discovery capabilities.

CorestemChemon's Neuronata-R Shows Significant Benefits in ALS Slow Progressors in Phase 3 Trial

Orphan DrugPrecision Medicine
  • CorestemChemon's Phase 3 ALSummit trial of Neuronata-R demonstrated statistically significant improvements in ALS patients classified as slow progressors, with meaningful gains in functional rating scales and respiratory capacity.
  • Biomarker analysis revealed sustained reductions in neurofilament light chain and MCP-1, indicating neuroprotective effects that support a precision-medicine approach for ALS treatment.
  • The company plans to pursue FDA accelerated approval pathway discussions in Q4 2025, with a Biologics License Application submission targeted for 2026 based on the subgroup efficacy data.

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS

NCT04745299Active, Not RecruitingPhase 3
Corestemchemon, Inc.
Posted 3/23/2021

Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

NCT01363401CompletedPhase 1
Corestemchemon, Inc.
Posted 2/1/2011

SOHM Secures South Korean Patent for CRISPR-Based Gene Editing Platform Targeting CAR-T Therapy Development

Gene EditingCAR-TPrecision Medicine
  • SOHM, Inc. received patent approval from South Korea for its ABBIE gene-editing platform that fuses dCas9 with retroviral integrases for targeted DNA integration.
  • The patent covers "CAS9 Retroviral Integrase and CAS9 Recombinase Systems" technology designed for site-specific genome incorporation in cells and organisms.
  • This Korean patent approval follows earlier European successes and strengthens SOHM's global intellectual property portfolio for next-generation allogeneic CAR-T therapies.
  • The ABBIE platform represents a first-in-class solution for precise gene integration with applications in regenerative medicine and therapeutic development.

Biocartis Receives FDA Approval for First Fully Automated Companion Diagnostic Test for Colorectal Cancer

FDA ApprovalPrecision Medicine
  • Biocartis has received FDA Premarket Approval for the Idylla™ CDx MSI Test, marking the first fully automated, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients.
  • The test identifies microsatellite instability-high (MSI-H) colorectal cancer patients who may benefit from treatment with OPDIVO® (nivolumab) alone or combined with YERVOY® (ipilimumab).
  • The diagnostic test delivers results in under three hours with less than three minutes of hands-on time, detecting seven monomorphic biomarkers for MSI detection in colorectal cancer tissue samples.
  • The approval was developed through a partnership with Bristol Myers Squibb and is supported by data from the CheckMate-8HW trial.

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Active, Not RecruitingPhase 3
Bristol-Myers Squibb
Posted 8/5/2019

Apollo Hospitals Invests Rs 573 Crore in Advanced Proton Therapy Oncology Center in Gurugram

OncologyCAR-TPrecision Medicine
  • Apollo Hospitals announces a Rs 573 crore investment to establish a 100-bed Comprehensive Oncology Centre in Gurugram featuring the Proteus One single gantry Proton Beam Therapy system.
  • The facility will mark Apollo's third proton therapy installation in India and is expected to serve an additional 350 patients annually by FY 2029.
  • Apollo aims to double its oncology business to over Rs 5,000 crore in the next 3-4 years through advanced treatments including proton therapy, robotics, immunotherapy, and CAR-T cell therapies.
  • The company simultaneously acquired IFC's 31% stake in Apollo Health and Lifestyle Ltd for Rs 1,254 crore to consolidate its healthcare portfolio operations.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.